Karolinska Development
An investment company that finances and supports innovative life science ventures.
KDEV | ST
Overview
Corporate Details
- ISIN(s):
- SE0002190850 (+1 more)
- LEI:
- 54930011ZA52NKO5W681
- Country:
- Sweden
- Address:
- Nanna Svartz väg 6A, 171 65 Solna
Description
Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-01-28 08:00 |
Karolinska Development AB utser ny finansdirektör
|
Swedish | 320.4 KB | ||
| 2014-01-28 08:00 |
Karolinska Development AB appoints new Chief Financial Officer
|
English | 412.0 KB | ||
| 2014-01-10 08:00 |
NovaSAID initiates partnership with Cadila Pharmaceuticals to develop innovativ…
|
English | 457.8 KB | ||
| 2014-01-10 08:00 |
NovaSAID inleder samarbete med Cadila Pharmaceuticals för utveckling av nya beh…
|
Swedish | 456.8 KB | ||
| 2013-12-27 08:00 |
Axelar rapporterar slutliga data från fas II-studie av AXL1717 vid lungcancer
|
Swedish | 443.4 KB | ||
| 2013-12-27 08:00 |
Axelar announces final data from Phase II study with AXL1717 in lung cancer
|
English | 455.4 KB | ||
| 2013-11-21 08:00 | Swedish | 971.9 KB | |||
| 2013-11-21 08:00 | English | 1003.6 KB | |||
| 2013-10-10 08:00 |
Pergamum announces final data from Phase I/II study of LL-37 in patients with c…
|
English | 347.8 KB | ||
| 2013-10-10 08:00 |
Pergamum rapporterar slutgiltigt resultat från fas I/II-studie med LL-37 på pat…
|
Swedish | 347.6 KB | ||
| 2013-08-27 08:00 |
Lipidor rapporterar positiva kliniska fas I/II-data vid behandling av psoriasis
|
Swedish | 343.4 KB | ||
| 2013-08-27 08:00 |
Lipidor reports positive clinical Phase I/II data in psoriasis
|
English | 344.4 KB | ||
| 2013-08-22 08:30 |
Purchase of own shares to cover social security fees related to incentive progr…
|
English | 317.2 KB | ||
| 2013-08-22 08:30 |
Återköp av egna aktier för att täcka sociala avgifter kopplade till incitaments…
|
Swedish | 319.0 KB | ||
| 2013-08-22 08:00 | Swedish | 957.1 KB |
Automate Your Workflow. Get a real-time feed of all Karolinska Development filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Karolinska Development
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Karolinska Development via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-04 | Johan Dighed | Other | Buy | 35,000 | 56,350.00 SEK |
| 2023-03-27 | Johan Dighed | Other | Buy | 50,000 | 89,000.00 SEK |
| 2023-02-17 | Hans Christopher Karl Osvald Perbandt Toll | Other | Buy | 35,000 | 72,100.00 SEK |
| 2022-12-19 | Johan Dighed | Other | Buy | 50,000 | 83,500.00 SEK |
| 2022-09-30 | Johan Dighed | Other | Buy | 40,187 | 72,336.60 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,014 | 25,780.04 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 5,000 | 14,350.00 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,276 | 26,529.36 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 4,645 | 13,331.15 SEK |
| 2020-06-23 | Hans Lennart Rudolf Wigzell | Other | Buy | 39,702 | 111,562.62 SEK |